ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF
申请人:EPIZYME, INC.
公开号:US20140323537A1
公开(公告)日:2014-10-30
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
Arginine methyltransferase inhibitors and uses thereof
申请人:Epizyme, Inc.
公开号:US09346761B2
公开(公告)日:2016-05-24
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF
申请人:EPIZYME, INC.
公开号:US20160137609A1
公开(公告)日:2016-05-19
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. Formula (I).
[5]helicene derivatives. C−H activation is facilitated by the presence of an ortho-activating group in the adjacent position. In the case of unsymmetrically substituted boronic acids, the regioselectivity of C−H activation is controlled by the electronic and stericeffects of the substituents.